WntResearch announced that the company has initiated a collaboration project with Business Sweden with the aim of establishing one or more commercial partnerships for the drug candidate Foxy-5 with Japanese and South Korean companies.  The collaboration takes place within the framework of Business Sweden's export project, which aims to introduce Swedish innovations to new international markets by promoting partnerships and networking, as well as providing financial support for research projects in small and medium-sized companies. Business Sweden will assist WntResearch in evaluating and establishing contact with potential partners for licensing or commercial collaboration agreements related to WntResearch's drug candidate Foxy-5. Within the project WntResearch has decided to prioritize pharmaceutical companies in the South Korean and Japanese markets to best leverage Business Sweden's network and deep industry knowledge there. The goal is to out-license Foxy-5 to a partner that has the ability to commercialize Foxy-5 on a regional or global level.

WntResearch is developing the drug candidate Foxy-5 as a new potential treatment for colon cancer. Foxy-5 is currently being evaluated in the ongoing clinical phase 2 study NeoFox, which will be conducted at several trial centers in Spain and Hungary. The aim is to establish proof of concept for the drug candidate in the treatment of patients with stage III colon cancer.